DKSH signs exclusive distribution agreement with Abitec

Published: 25-Jul-2018

The ingredients and specialty chemicals distributor has been selected to exclusively distribute a lipid excipient and nutritional supplement range in Thailand, Spain and Portugal

DKSH, a market expansion services provider, has been appointed by Abitec, developer and manufacturer of specialty lipids, as the exclusive distributor of Abitec’s range of lipid-based excipients and nutritional supplements in Thailand, Spain and Portugal. DKSH will also distribute these products in Italy and Greece on a non-exclusive basis.

Abitec’s lipid-based excipients enhance the bioavailability of poorly water-soluble and poorly permeable active pharmaceutical ingredients (APIs). They may be utilised in the formulation of a self-emulsifying drug delivery System (SEDDS), as well as in other applications for improved solubilisation, emulsification and lubrication.

Abitec’s trademarked specialty lipids include Capmul, Captex, Caprol, Acconon, Sterotex, Nutri Sperse, Hydro-Kote and Pureco. Their application area varies from pharmaceutical, nutritional and cosmetic products, to the manufacturing of foams, creams, ointments and lotions. The range is produced in ISO-certified facilities in accordance with cGMP and IPEC guidelines.

Under the agreement, DKSH will market and distribute ABITEC’s specialty ingredients to a large customer base in Thailand, Spain, Portugal, Italy and Greece.

DKSH was chosen for its solid logistics infrastructure and proven experience in providing Market Expansion Services along the entire value chain. DKSH also currently works with ABITEC’s parent company Associated British Foods in many Asian markets.

Tanja Schaffer, VP, Pharmaceutical Industry, DKSH, commented: “We are delighted to partner with ABITEC in multiple countries across Europe and in Asia. Their innovative lipid solutions strengthen our existing portfolio and will provide exciting new opportunities in the field of formulation development for our loyal customer base in some of our key pharmaceutical markets.”

You may also like